Myelodysplastic Syndrome (MDS)

Intermediate and/or High Risk

**Newly diagnosed**
- IRB# 16867: Abbvie 531 phase 1b venetoclax + azacitidine in treatment naïve subjects
- IRB# 16964: FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
- IRB# 15977: Non Treatment National MDS Study (ECOG/ACRIN)
- IRB# 17379: Novartis Phase 1B PDR001 and/or MBG453 with decitabine
- IRB# 18809: Renal Impairment Study of CPX-351 (Vyxeos)
- IRB# 20743: Study coming soon

**Relapsed/ refractory**
- IRB# 16984: Abbvie 522 venetoclax by itself or in combination with azacitidine in relapsed/refractory subjects
- IRB# 19290: Ph 1b Dose-escalation of PLX2853
- IRB# 17379: Novartis Phase 1B PDR001 and/or MBG453 with decitabine
- IRB# 18809: Renal Impairment Study of CPX-351 (Vyxeos)
- IRB# 17577, 21165: Studies coming soon

**Lower Risk**
- IRB# 19978: Study coming soon

**Cross Disease Trial**
- IRB# 19992: EAY131 (MATCH)

3/18/2020

http://www.ohsu.edu/research/rda/so/knight.php